Lipocine Inc. Files 8-K for Other Events
Ticker: LPCN · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Update
TL;DR
Lipocine filed an 8-K, expect updates soon.
AI Summary
Lipocine Inc. filed an 8-K on September 5, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but it serves as a notification of these items.
Why It Matters
This filing indicates Lipocine Inc. is providing updates on its corporate activities and financial status to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a routine procedural update and does not contain information that inherently increases risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- September 5, 2024 (date) — Date of Earliest Event Reported
- 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
- Salt Lake City, Utah 84108 (address) — Principal executive offices
- 801-994-7383 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K?
The provided text of the 8-K filing does not specify the details of the 'Other Events'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 5, 2024.
What is the principal executive office address for Lipocine Inc.?
The principal executive office address for Lipocine Inc. is 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is the SEC file number for Lipocine Inc.?
The SEC file number for Lipocine Inc. is 001-36357.
Does this filing include specific financial statement details?
The filing is categorized to include 'Financial Statements and Exhibits', but the provided text does not contain the specific details of these statements.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-09-05 09:35:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 17KB
- form8-k_001.jpg (GRAPHIC) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 8KB
- 0001493152-24-035104.txt ( ) — 263KB
- lpcn-20240905.xsd (EX-101.SCH) — 3KB
- lpcn-20240905_lab.xml (EX-101.LAB) — 33KB
- lpcn-20240905_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: September 5, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer